Table 1 Patient and tumour characteristics (n=351)

Median follow-up (months)

59.3 (16.5-82.6)

Gland volume at implant (cc)

   mean

41

   median

39 (16–107)

Age at treatment (years)

   mean

67.7

   median

68.4 (44.1-82.2)

Pre-treatment PSA (ng/ml)

   mean

7.1

   median

6.4 (2.0-34.1)

n (%)

Stage

   T1b-c

129 (36.7%)

   T2a

113 (32.1%)

   T2b

55 (15.6%)

   T2c

53 (15.0%)

   T3a

1 (0.2%)

Gleason score

   ≤ 6

281 (80.0%)

   7

62 (17.6%)

   > 7

8 (2.2%)

Pre-treatment PSA (ng/ml)

   ≤ 10

324 (92.3%)

   11-20

23 (6.5%)

   > 20

4 (1.1%)

Age at treatment (years)

   < 60

51 (14.5%)

   60-69

169 (48.1%)

   ≥ 70

131 (37.3%)

Androgen deprivation therapy

70 (19.9%)

Risk group

   Low

196 (55.8%)

   Intermediate

81 (23.0%)

   High

74 (21.0%)